<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="preparation" /><meta name="keywords" content="Revlimid; Lenalidomide" /><meta name="IX" content="Revlimid; Lenalidomide" /><title>Revlimid®: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="59/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="PHP5714-revlimid.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="PHP5714-revlimid.htm#pB" title="Skip Navigation">Skip Navigation</a><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=PHP5714-revlimid.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 08 Oct 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF September 2012</a> &gt; <a href="PHP5179-malignant-disease-and-immunosuppression.htm">8 Malignant disease and immunosuppression</a> &gt; <a href="PHP5590-drugs-affecting-the-immune-response.htm">8.2 Drugs affecting the immune response</a> &gt; <a href="PHP5665-other-immunomodulating-drugs.htm">8.2.4 Other immunomodulating drugs</a> &gt; <a href="PHP5709-lenalidomide-and-thalidomide.htm">Lenalidomide and thalidomide</a> &gt; <a href="PHP5713-lenalidomide.htm">LENALIDOMIDE</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="PHP5709-lenalidomide-and-thalidomide.htm" title="Previous: Lenalidomide and thalidomide">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="PHP5715-thalidomide.htm" title="Next: THALIDOMIDE">Next page</a> ►</div></div></div></div><div id="p1"><div id="sideBar"><h2>See Also</h2><ul><li><h3>AHFS Drug Information</h3></li><li><a href="http://www.medicinescomplete.com/mc/ahfs/2010/a306005.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Lenalidomide</a><div class="breadcrumb"><p><strong>AHFS Drug Information</strong> &gt; Antineoplastic Agents 10:00</p></div></li></ul><ul><li><h3>Stockley's Interaction Alerts</h3></li><li><a href="http://www.medicinescomplete.com/mc/alerts/2010/21031-z.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Lenalidomide</a><div class="breadcrumb"><p><strong>Stockley's Interaction Alerts</strong> &gt; Interactants: L &gt; Interactions of Lenalidomide</p></div></li></ul><ul><li><h3>British National Formulary (2)</h3></li><li><a href="PHP5709-lenalidomide-and-thalidomide.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Lenalidomide and thalidomide</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 8 Malignant disease and immunosuppression &gt; 8.2 Drugs affecting the immune response &gt; 8.2.4 Other immunomodulating drugs</p></div></li><li><a href="PHP5713-lenalidomide.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">LENALIDOMIDE</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 8 Malignant disease and immunosuppression &gt; 8.2 Drugs affecting the immune response &gt; 8.2.4 Other immunomodulating drugs &gt; Lenalidomide and thalidomide</p></div></li></ul><ul><li><h3>Martindale: The Complete Drug Reference (2)</h3></li><li><a href="http://www.medicinescomplete.com/mc/martindale/2009/21031-z.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Lenalidomide</a><div class="breadcrumb"><p><strong>Martindale: The Complete Drug Reference</strong> &gt; Drugs and Ancillary Substances &gt; By therapeutic use &gt; Antineoplastics &gt; Drug Monographs</p></div></li><li><a href="http://www.medicinescomplete.com/mc/martindale/2009/24935-w.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Pomalidomide</a><div class="breadcrumb"><p><strong>Martindale: The Complete Drug Reference</strong> &gt; Drugs and Ancillary Substances &gt; By therapeutic use &gt; Antineoplastics &gt; Drug Monographs</p></div></li></ul><ul><li><h3>The Merck Index</h3></li><li><a href="http://www.medicinescomplete.com/mc/merck/2010/05436.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Lenalidomide</a><div class="breadcrumb"><p><strong>The Merck Index</strong> &gt; Monographs &gt; L &gt; LE</p></div></li></ul><ul><li><h3>Remington: The Science and Practice of Pharmacy</h3></li><li><a href="http://www.medicinescomplete.com/mc/rem/2012/mono-L13.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Lenalidomide</a><div class="breadcrumb"><p><strong>Remington: The Science and Practice of Pharmacy</strong> &gt; Part 3: Pharmaceutical and Medicinal Agents &gt; L</p></div></li></ul><ul><li><h3>Stockley's Drug Interactions</h3></li><li><a href="http://www.medicinescomplete.com/mc/stockley/2010/int-E2E0E6E3E0R0D1486.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Lenalidomide</a><div class="breadcrumb"><p><strong>Stockley's Drug Interactions</strong> &gt; Interactants, Alphabetically &gt; L</p></div></li></ul><script type="text/javascript" src="scripts/sidebar.js"></script></div><div id="pB"><h1>LENALIDOMIDE</h1><?highlighter on?><div id="pC" class="jN"><div class="cL"><div class="cE"><h3 class="cO">Additional information</h3> <p class="cT"> interactions (<a href="bnf_int1106-lenalidomide.htm">Lenalidomide</a>).</p></div></div><div class="cL"><div class="cE"><h2 class="cN">Indications </h2> <p class="cT">see <a title="target-block: Lenalidomide notes" href="PHP5709-lenalidomide-and-thalidomide.htm#PHP5710">notes above</a></p></div> </div> <div class="cL"><div class="cE"><h2 class="cN">Cautions </h2> <p class="cT">see <a title="target-block: Lenalidomide notes" href="PHP5709-lenalidomide-and-thalidomide.htm#PHP5710">notes above</a>; monitor full blood count (including differential white cell count and platelet count) before treatment and every week for the first 8 weeks then every 4 weeks (reduce dose or interrupt treatment if neutropenia or thrombocytopenia develop—consult product literature); monitor for arterial or venous thromboembolism (consider permanent discontinuation if thromboembolic event occurs) and use caution with concomitant drugs that increase the risk of thromboembolism—see also Thromboembolism below; high tumour burden—risk of <a title="BNF:target-block: Tunour lysis syndrome" href="PHP5183-side-effects-of-cytotoxic-drugs.htm#PHP5186">tumour lysis syndrome</a>; monitor thyroid function; risk factors for myocardial infarction; <strong>interactions:</strong> Appendix 1 (lenalidomide)</p></div> <div class="cG"><div class="cE"><h3 class="cT">Thromboembolism</h3> <p class="cT">Risk factors for thromboembolism (such as smoking, hypertension, hyperlipidaemia) should be minimised and thromboprophylaxis should be considered in patients with multiple risk factors.</p></div><p>Patients and their carers should be made aware of the symptoms of thromboembolism and advised to report sudden breathlessness, chest pain, or swelling of a limb</p></div> <div class="cG"><div class="cE"><h3 class="cT">Neutropenia and thrombocytopenia</h3> <p class="cT">Patients and their carers should be made aware of the symptoms of neutropenia and advised to seek medical advice if symptoms suggestive of neutropenia (such as fever, sore throat) or of thrombocytopenia (such as bleeding) develop</p></div></div> <div class="cG"><div class="cE"><h3 class="cT">Second primary malignancy </h3> <p class="cT">Patients should be carefully evaluated before and during treatment with lenalidomide using routine cancer screening for occurrence of second primary malignancy and treatment should be instituted as indicated</p></div></div> </div> <div class="cL"><div class="cE"><h2 class="cN">Renal impairment </h2> <p class="cT">starting dose 10 mg once daily if creatinine clearance 30–50 mL/minute; starting dose 15 mg on alternate days if creatinine clearance less than 30 mL/minute</p></div> </div> <div class="cL"><div class="cE"><h2 class="cN">Pregnancy </h2> <p class="cT"><strong>important: teratogenic risk</strong>; see also <a title="BNF:target-block: Lenalidomide and thalidomide prgenancy notes" href="PHP5709-lenalidomide-and-thalidomide.htm#PHP5712">notes above</a></p></div> </div> <div class="cL"><div class="cE"><h2 class="cN">Breast-feeding </h2> <p class="cT">discontinue breast-feeding—no information available</p></div> </div> <div class="cL"><div class="cE"><h2 class="cN">Side-effects </h2> <p class="cT">myocardial infarction, hypotension, deep vein thrombosis; pneumonia, dyspnoea; tremor, hypoaesthesia, fatigue, asthenia; neutropenia, thrombocytopenia, anaemia, lymphopenia, leucopenia; muscle cramp; pruritus, rash; <em>rarely</em> Stevens-Johnson syndrome and toxic epidermal necrolysis; <em>also reported</em> interstitial pneumonitis, pancreatitis, pulmonary embolism, cerebrovascular events, secondary malignancies</p></div> </div> <div class="cL"><h2 class="cM">Dose</h2><div class="cR"><ul><li><p><span class="cP">adult</span> over 18 years, 25 mg once daily for 21 consecutive days of a 28-day cycle; for doses of dexamethasone, consult product literature</p></li> </ul></div></div> </div><div id="pS"><p>Sub-sections</p><div id="PHP5714-revlimid" style="margin: 0 0 0 20px;"><h1 class="title">Revlimid® <span>(<a href="PHP10005-index-of-manufacturers.htm#PHP10083">Celgene</a>)</span><span> <img src="images/pom_l.png" alt="Prescription only medicine" /></span></h1><div class="cU"><p><strong>Capsules</strong>, lenalidomide, 5 mg (white), net price 21-cap pack = £3570.00; 10 mg (blue/yellow), 21-cap pack = £3780.00; 15 mg (blue/white), 21-cap pack = £3969.00; 25 mg (white), 21-cap pack = £4368.00. Label: 25, counselling, symptoms of thromboembolism, neutropenia, or thrombocytopenia, patient information leaflet</p><div class="cG"><div class="cE"><h3 class="cT">Note </h3> <p class="cT">Patient, prescriber, and supplying pharmacy must comply with a pregnancy prevention programme. Every prescription must be accompanied by a completed Prescription Authorisation Form, which must be sent to Celgene.</p></div></div></div></div></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="PHP5709-lenalidomide-and-thalidomide.htm">Previous: Lenalidomide and thalidomide</a> | <a class="top" href="PHP5714-revlimid.htm#">Top</a> | <a accesskey="]" href="PHP5715-thalidomide.htm">Next: THALIDOMIDE</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and Pharmaceutical Press 2012. All rights reserved. </a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>